Harrison Lab

Publications

Nicosia, L; Pranke, I; Latorre, RV; Murray, JB; Lonetti, L; Cavusoglu-Doran, K; Dreano, E; Costello, JP; Carroll, M; Melotti, P; Sorio, C; Sermet-Gaudelus, I; Scallan, MF; Harrison, PT. Adenine base editing with engineered virus-like particles rescues the CFTR mutation G542X in patient-derived intestinal organoids. iScience. 2025; 28:111979.

Murray, JB; Harrison, PT; Scholefield, J. Prime editing: therapeutic advances and mechanistic insights. Gene Therapy (Basingstoke). 2025; 32:83-92.

Weimann, A; Dinan, AM; Ruis, C; Bernut, A; Pont, S; Brown, K; Ryan, J; Santos, L; Ellison, L; Ukor, E; Fothergill, JL; Levesque, RC; Parkhill, J; Floto, RA. Evolution and host-specific adaptation of Pseudomonas aeruginosa. Science. 2024; 385:eadi0908.

Walker, AJ; Graham, C; Greenwood, M; Woodall, M; Maeshima, R; O'Hara-Wright, M; Sanz, DJ; Guerrini, I; Aldossary, AM; O'Callaghan, C; Baines, DL; Harrison, PT; Hart, SL. Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing. Molecular Therapy-Methods & Clinical Development. 2023; 31:101140.

Santos, L; Nascimento, R; Duarte, A; Railean, V; Amaral, MD; Harrison, PT; Gama-Carvalho, M; Farinha, CM. Mutation-class dependent signatures outweigh disease-associated processes in cystic fibrosis cells. Cell and Bioscience. 2023; 13:26.

Mention, K; Cavusoglu-Doran, K; Joynt, AT; Santos, L; Sanz, D; Eastman, AC; Merlo, C; Langfelder-Schwind, E; Scallan, MF; Farinha, CM; Cutting, GR; Sharma, N; Harrison, PT. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X. Human Molecular Genetics. 2023; 32:3237-3248.

Harrison, P; Friedmann, T. Cost of gene therapy. Gene Therapy (Basingstoke). 2023; 30:737.

Egan, ME; Harrison, PT. Gene and Rna-Based Therapies. Hodson and Geddes' Cystic Fibrosis. : Taylor & Francis; Taylor & Francis; 2023.

Amaral, MD; Harrison, PT. Development of novel therapeutics for all individuals with CF (the future goes on). Journal of Cystic Fibrosis. 2023; 22 Suppl 1:S45-S49.

Harrison, PT. CFTR RNA- and DNA-based therapies. Current Opinion in Pharmacology. 2022; 65:102247.

Harrison, PT. CRISPR gene editing - what are the possibilities for respiratory medicine?. Expert Review of Respiratory Medicine. 2022; 16:371-374.

Santos, L; Mention, K; Cavusoglu-Doran, K; Sanz, DJ; Bacalhau, M; Lopes-Pacheco, M; Harrison, PT; Farinha, CM. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation. Journal of Cystic Fibrosis. 2022; 21:181-187.

Cheung, PY; Harrison, PT; Davidson, AJ; Hollywood, JA. In Vitro and In Vivo Models to Study Nephropathic Cystinosis. Cells. 2022; 11:6.

Mussolino, C; Harrison, P. Spotlight on gene therapy in Germany. Gene Therapy (Basingstoke). 2021; 28:471-472.

Scholefield, J; Harrison, PT. Prime editing - an update on the field. Gene Therapy (Basingstoke). 2021; 28:396-401.

Price, E; Gianfrancesco, O; Harrison, PT; Frank, B; Bubb, VJ; Quinn, JP. CRISPR Deletion of a SVA Retrotransposon Demonstrates Function as a cis-Regulatory Element at the TRPV1/TRPV3 Intergenic Region. International Journal of Molecular Sciences. 2021; 22:1911.